CENTRAL ISLIP, N.Y.–(BUSINESS WIRE)–CVD Equipment Corporation (NASDAQ: CVV), a leading provider of chemical vapor deposition systems and materials, announced today that it has received an Applied Research & Development (ARaD) award in collaboration with the Renaissance School of Medicine from the NY State Center of Biotechnology at Stony Brook University.
In a separate press release on July 24, 2019, the Center of Biotechnology at Stony Brook University announced it will be supporting further development of CVD’s project for “c-VACNT™ material bio-interaction studies.” This collaboration will support continued development of CVD’s advanced carbon-based fluid reactors which it first announced in press releases on November 14, 2018 and November 26, 2018.
CVD has developed a novel, patent-pending, fluid reactor system that is targeted to enable the design and manufacturing of an improved Extracorporeal Membrane Oxygenation (ECMO) device. ECMO devices are utilized in heart-lung machines. Potential benefits include reduced blood priming volume (especially for neonatal use), lower blood trauma (hemolysis), and the ability to design portable artificial lungs that operate without a blood pump and utilize ambient air instead of pure oxygen for increased patient mobility or in special logistically challenged situations.
This technology also has potential use in other fluid reaction-based applications such as dialysis, water desalination, membrane distillation, chemical, pharma and biomaterials manufacturing. These fluid reactor devices are enabled by a family of novel Reactor Core Elements (RCE) made from free-standing, self-supporting, carbon-infiltrated c-VACNT™ material.
Dr. Srinivas Pentyala, Professor & Director of Translational Research of Anesthesiology and Faculty Member in Urology, Health Sciences, Physiology & Biophysics at the Renaissance School of Medicine at Stony Brook University, and the principal investigator of the ARaD grant stated that “Preliminary in-vitro testing of the bio-compatibility and interaction of coated c-VACNT™ – structures with bovine blood have been encouraging. I’m excited to continue to investigate the potential of c-VACNT™ – structures for a broad range of medical applications. In particular, we will be investigating if the significant performance gains demonstrated by CVD’s Application Laboratory with water for oxygenation/deoxygenation will also translate to venus blood oxygenation and carbon dioxide removal under ISO 7199 test conditions as recommended by the FDA.”
“We are excited to work together with the Renaissance School of Medicine to investigate the ECMO product and other medical potential of our c-VACNT™ material platform,” said Leonard Rosenbaum, President and Chief Executive Officer of CVD. Mr. Rosenbaum further stated that “continued innovations in nanotechnology applications can lead to advanced medical products capable of ‘improving quality of life’ for the end user – in this case the patient.”
The Center for Biotechnology’s Applied Research and Development Program currently provides matching funds on a competitive basis to support collaborations between the Stonybrook University faculty and NY State corporate partners in all areas of medical biotechnology. The primary interest of the program is to support development of technologies that will help companies meet commercially relevant milestones that have the potential to positively impact the New York State economy.
For more information please visit: https://www.cvdequipment.com/2019/06/
About CVD Equipment Corporation
CVD Equipment Corporation (NASDAQ: CVV) designs, develops, and manufactures a broad range of chemical vapor deposition, gas control, and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for research and industrial applications. This equipment is used by its customers to research, design, and manufacture these materials or coatings for aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS, and other applications. Through its application laboratory, the Company provides process development support and process startup assistance with the focus on enabling tomorrow’s technologies™. It’s wholly owned subsidiary CVD Materials Corporation provides advanced materials and metal surface treatments and coatings to serve demanding applications in the electronic, biomedical, petroleum, pharmaceutical, and many other industrial markets.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by CVD Equipment Corporation) contains statements that are forward-looking. All statements other than statements of historical fact are hereby identified as “forward-looking statements, “as such term is defined in Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward looking information involves a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those discussed or anticipated by management. Potential risks and uncertainties include, among other factors, conditions, success of CVD Equipment Corporation’s growth and sales strategies, the possibility of customer changes in delivery schedules, cancellation of orders, potential delays in product shipments, delays in obtaining inventory parts from suppliers and failure to satisfy customer acceptance requirements.
Contacts
For further information about this topic please contact:
Thomas McNeill
Phone: (631) 981-7081
Fax: (631) 981-7095
Email: investorrelations@cvdequipment.com